[go: up one dir, main page]

WO2010009465A3 - Htlv-ii vector and methods of use - Google Patents

Htlv-ii vector and methods of use Download PDF

Info

Publication number
WO2010009465A3
WO2010009465A3 PCT/US2009/051138 US2009051138W WO2010009465A3 WO 2010009465 A3 WO2010009465 A3 WO 2010009465A3 US 2009051138 W US2009051138 W US 2009051138W WO 2010009465 A3 WO2010009465 A3 WO 2010009465A3
Authority
WO
WIPO (PCT)
Prior art keywords
htlv
viral
methods
vector
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/051138
Other languages
French (fr)
Other versions
WO2010009465A2 (en
Inventor
Genoveffa Franchini
Izabela Bialuk
Vibeke Andresen
Shari Gordon
Valentina Cecchinato
Francis Ruscetti
Kathryn Jones
Christophe Pierre Marie Nicot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2010009465A2 publication Critical patent/WO2010009465A2/en
Publication of WO2010009465A3 publication Critical patent/WO2010009465A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14051—Methods of production or purification of viral material
    • C12N2740/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The disclosure provides compositions and methods of use of an HTLV-II viral vector. In embodiments, the disclosure provides an isolated viral vector comprising at least a portion of the HTLV-II genome encoding the gag, pro, and pol genes and lacking all or a portion of the pX region and a polynucleotide encoding all or a portion of a protein that corresponds to a viral protein from a heterologous virus located within the deletion in the pX region. The viral vectors are useful for inducing an immune response to the viral protein form the heterologous virus.
PCT/US2009/051138 2008-07-18 2009-07-20 Htlv-ii vector and methods of use Ceased WO2010009465A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8199408P 2008-07-18 2008-07-18
US61/081,994 2008-07-18

Publications (2)

Publication Number Publication Date
WO2010009465A2 WO2010009465A2 (en) 2010-01-21
WO2010009465A3 true WO2010009465A3 (en) 2010-03-25

Family

ID=41091781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051138 Ceased WO2010009465A2 (en) 2008-07-18 2009-07-20 Htlv-ii vector and methods of use

Country Status (1)

Country Link
WO (1) WO2010009465A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5999703B2 (en) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 HLA-DR1-restricted Tax-specific CD4 + T cell epitope
CN108546679B (en) * 2018-04-23 2021-04-16 北京翊博普惠生物科技发展有限公司 A method for massive expansion of human mature hyperactive dendritic cells in vitro and its application
CN111041048B (en) * 2019-12-30 2021-07-06 北京鼎成肽源生物技术有限公司 A kind of preparation method of trophoblast of limited generation and culture method of SNK cell
CN114134182B (en) * 2021-08-26 2025-10-10 北京新源生物制品有限公司 Preparation method of a novel immune cell and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031119A1 (en) * 1996-02-21 1997-08-28 Res Inst For Genetic And Human Methods and compositions for protective and therapeutic genetic immunization
WO1999019501A1 (en) * 1997-10-14 1999-04-22 Institute For Vaccine Development Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031119A1 (en) * 1996-02-21 1997-08-28 Res Inst For Genetic And Human Methods and compositions for protective and therapeutic genetic immunization
WO1999019501A1 (en) * 1997-10-14 1999-04-22 Institute For Vaccine Development Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COCKERELL G L ET AL: "A deletion in the proximal untranslated pX region of human T-cell leukemia virus type II decreases viral replication but not infectivity in vivo.", BLOOD 1 FEB 1996, vol. 87, no. 3, 1 February 1996 (1996-02-01), pages 1030 - 1035, XP002548472, ISSN: 0006-4971 *
COVAS DIMAS TADEU ET AL: "Complete nucleotide sequences of the genomes of two Brazilian specimens of human T lymphotropic virus type 2 (HTLV-2).", AIDS RESEARCH AND HUMAN RETROVIRUSES AUG 2003, vol. 19, no. 8, August 2003 (2003-08-01), pages 689 - 697, XP002548473, ISSN: 0889-2229 *
DESROSIERS C R ET AL: "Prospects for an AIDS vaccine", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 3, 1 March 2004 (2004-03-01), pages 221 - 223, XP002988967, ISSN: 1078-8956 *
JOURNAL OF VIROLOGY JUL 2005, vol. 79, no. 14, July 2005 (2005-07-01), pages 8828 - 8834, XP002563235, ISSN: 0022-538X *
LYNCH MARCUS P ET AL: "Advances in HTLV-1 peptide vaccines and therapeutics.", CURRENT PROTEIN & PEPTIDE SCIENCE APR 2006, vol. 7, no. 2, April 2006 (2006-04-01), pages 137 - 145, XP009123649, ISSN: 1389-2037 *

Also Published As

Publication number Publication date
WO2010009465A2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
AU2014203512B2 (en) Recombinant virus-like particles encoded by multi-gene vector
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
EP3597760A3 (en) Adeno-associated virus vector
MX2018010824A (en) Inducible binding proteins and methods of use.
EA201692359A1 (en) COMPOSITION BASED ON NEW PRRSV STRAIN OR HIS PROTEINS, PRODUCT, THEIR USE, PRRSV VIRUS, ISOLATED NK AND A RECOMBINANT VECTOR OF EXPRESSION FOR OBTAINING THIS VIRUS
MX2017002791A (en) Recombinant modified vaccinia virus ankara (mva) filovirus vaccine.
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2008115199A3 (en) Chimeric virus vaccines
MY173638A (en) Parainfluenza virus 5 based vaccines
WO2010105251A3 (en) Non-integrating retroviral vector vaccines
MX361893B (en) Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof.
IN2015DN02546A (en)
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
MX2008016036A (en) Recombinant viral vaccine.
MX354516B (en) Vectors encoding rod-derived cone viability factor.
MX2009010492A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells.
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
WO2018060368A3 (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
IN2015DN03206A (en)
WO2014036468A3 (en) Aav mediated aquaporin gene transer to treat sjogren's syndrome
MX2020003071A (en) Paramyxoviridae expression system.
WO2010009465A3 (en) Htlv-ii vector and methods of use
MX390966B (en) Dengue vaccines
WO2012116253A3 (en) Recombinant mumps virus vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09790634

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09790634

Country of ref document: EP

Kind code of ref document: A2